At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Tarceva (Erlotinib) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating bevacizumab, erlotinib hydrochloride, and 5 other interventions for Melanoma. Completed, enrolled 34 participants across 4 sites.
Detailed Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IV melanoma.
Study Details
Timeline
Interventions
10mg/kg, slow IV infusion, Days 1 and 14
150mg PO qd
Targeting multiple genetic aberrations in isolated tumor cells.
gene expression analysis
immunologic technique
laboratory biomarker analysis
biopsy